Ascendis Pharma A (ASND) Cash from Investing Activities (2014 - 2026)

Ascendis Pharma A (ASND) has 13 years of Cash from Investing Activities data on file, last reported at -$7.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 969.14% year-over-year to -$7.9 million; the trailing twelve-month figure through Mar 2026 stood at -$16.8 million (down 1532.97% YoY), and the FY2025 full-year result was -$9.9 million, down 232.41% from the prior year.
• Cash from Investing Activities declined to -$7.9 million in Q1 2026, from -$3.9 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $226.1 million in Q1 2023 to a low of -$7.9 million in Q1 2026.
• A 5-year average of $21.5 million and a median of $654747.6 in 2024 frame the typical range for Cash from Investing Activities.
• Across the five-year window, Cash from Investing Activities surged 980.06% in 2023 and tumbled 969.14% in 2026, its largest moves.
• Tracing ASND's Cash from Investing Activities over 5 years: stood at -$813137.2 in 2022, then jumped by 980.06% to $7.2 million in 2023, then slumped by 105.5% to -$393243.1 in 2024, then sank by 903.77% to -$3.9 million in 2025, then tumbled by 100.29% to -$7.9 million in 2026.
• Business Quant data shows ASND's Cash from Investing Activities at -$7.9 million in Q1 2026, -$3.9 million in Q4 2025, and -$61959.9 in Q3 2025.